209 related articles for article (PubMed ID: 24623796)
1. Sudemycin E influences alternative splicing and changes chromatin modifications.
Convertini P; Shen M; Potter PM; Palacios G; Lagisetti C; de la Grange P; Horbinski C; Fondufe-Mittendorf YN; Webb TR; Stamm S
Nucleic Acids Res; 2014 Apr; 42(8):4947-61. PubMed ID: 24623796
[TBL] [Abstract][Full Text] [Related]
2. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.
Corrionero A; Miñana B; Valcárcel J
Genes Dev; 2011 Mar; 25(5):445-59. PubMed ID: 21363963
[TBL] [Abstract][Full Text] [Related]
3. Sudemycin K: A Synthetic Antitumor Splicing Inhibitor Variant with Improved Activity and Versatile Chemistry.
Makowski K; Vigevani L; Albericio F; Valcárcel J; Álvarez M
ACS Chem Biol; 2017 Jan; 12(1):163-173. PubMed ID: 28103691
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
[TBL] [Abstract][Full Text] [Related]
5. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors.
Cretu C; Gee P; Liu X; Agrawal A; Nguyen TV; Ghosh AK; Cook A; Jurica M; Larsen NA; Pena V
Nat Commun; 2021 Jul; 12(1):4491. PubMed ID: 34301950
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.
Folco EG; Coil KE; Reed R
Genes Dev; 2011 Mar; 25(5):440-4. PubMed ID: 21363962
[TBL] [Abstract][Full Text] [Related]
8. SF3B1 association with chromatin determines splicing outcomes.
Kfir N; Lev-Maor G; Glaich O; Alajem A; Datta A; Sze SK; Meshorer E; Ast G
Cell Rep; 2015 Apr; 11(4):618-29. PubMed ID: 25892229
[TBL] [Abstract][Full Text] [Related]
9. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
[TBL] [Abstract][Full Text] [Related]
10. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
[TBL] [Abstract][Full Text] [Related]
11. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
[TBL] [Abstract][Full Text] [Related]
12. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
Kaida D; Motoyoshi H; Tashiro E; Nojima T; Hagiwara M; Ishigami K; Watanabe H; Kitahara T; Yoshida T; Nakajima H; Tani T; Horinouchi S; Yoshida M
Nat Chem Biol; 2007 Sep; 3(9):576-83. PubMed ID: 17643111
[TBL] [Abstract][Full Text] [Related]
13. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
14. Modulation of alternative splicing by expression of small nuclear ribonucleoprotein polypeptide N.
Lee MS; Lin YS; Deng YF; Hsu WT; Shen CC; Cheng YH; Huang YT; Li C
FEBS J; 2014 Dec; 281(23):5194-207. PubMed ID: 25238490
[TBL] [Abstract][Full Text] [Related]
15. Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation.
Yoshimoto R; Chhipi-Shrestha JK; Schneider-Poetsch T; Furuno M; Burroughs AM; Noma S; Suzuki H; Hayashizaki Y; Mayeda A; Nakagawa S; Kaida D; Iwasaki S; Yoshida M
Cell Chem Biol; 2021 Sep; 28(9):1356-1365.e4. PubMed ID: 33784500
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin.
Murthy T; Bluemn T; Gupta AK; Reimer M; Rao S; Pillai MM; Minella AC
J Biol Chem; 2018 Jun; 293(26):10220-10234. PubMed ID: 29764937
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
18. [Discovery of splicing inhibitors and its impact on drug development].
Kotake Y; Kaida D; Mizui Y; Yoshida M
Tanpakushitsu Kakusan Koso; 2008 Jan; 53(1):28-35. PubMed ID: 18186300
[No Abstract] [Full Text] [Related]
19. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells.
Gao Y; Koide K
ACS Chem Biol; 2013 May; 8(5):895-900. PubMed ID: 23485022
[TBL] [Abstract][Full Text] [Related]
20. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation.
Roybal GA; Jurica MS
Nucleic Acids Res; 2010 Oct; 38(19):6664-72. PubMed ID: 20529876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
